With nearly 215 million new cases in 2015, the most recent year for which World Health Organization data is published, resulting in over 400,000 deaths, malaria continues as the scourge of tropics, especially Africa and Southeast Asia.  Despite the success of artemisinin based combination therapies, the plasmodium continues to develop drug resistance.  Therefore the need for new artemisinin codrugs as well as new classes of anti-malarials continues.  Recently, GlaxoSmithKline and other organizations have published a variety of vetted structural motifs that are potential candidates for the next line of antimalarials.  Currently we are investigating the synthesis of a series of tertiary cyanobenzamides based on one such a structural motif.  We report progress to date on a convergent synthesis route to a variety of these benzamides bearing substituted imidazolyl groups as well as a small alkyl group.

Tertiary benzamides as possible antimalarial leads

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.